[2009 Nov 15]
Chinese health officials reported on Friday the first deaths in people who received the H1N1 vaccine.
ttp://www.time.com/time/health/article/0,8599,1939575,00.html
Chinese health officials reported on Friday the first deaths in people who
received the H1N1 vaccine. The Ministry of Health announced that the two people,
including one teacher from Hunan province, died hours after receiving their
inoculations. Since September, when the Ministry began its H1N1 immunization
program, 12 million Chinese have received the pandemic flu shot.
A preliminary autopsy revealed that the teacher died of an apparent heart attack
while playing basketball, and a Ministry spokesperson told the China Daily
newspaper that the death was "a coincidental medical incident" and not related
to the vaccine. No details on the second victim have been released so far. (See
pictures :"Soccer in the Time of Swine Flu")
As they conduct an autopsy investigation into the second death, Chinese health
officials have pulled all vaccines manufactured in the same batch used to
inoculate the teacher. Although the H1N1 vaccine has been rigorously tested and
vetted for safety, no inoculation can be considered 100% safe and may cause
adverse events, including death, in some people.
Taking an aggressive approach to the pandemic flu, back in June the Chinese
government asked 11 biotech companies to develop a pandemic H1N1 vaccine.
Beijing-based Sinovac succeeded in developing the world's first approved swine
flu shot. The company raced to conduct clinical trials, and was the first to
report that a single dose of vaccine, instead of the two doses that most flu
experts had believed would be necessary, was sufficient to protect against 2009
H1N1. In early September, China became the first country to begin swine flu
inoculations.
But by the end of October, 54% of Chinese residents reported in a China Daily
survey that they would not get the H1N1 vaccine because of concerns about the
shot's safety. That prompted the director of the World Health Organization's
Beijing office, Dr. Michael O'Leary, to tell the newspaper, "The H1N1 vaccine is
one of the safest vaccines being used. When it's available to me, I would not
hesitate to get the vaccine developed and produced by China." (Read "H1N1:
Hitting the Young, Riskier for the Old")
Three vaccine manufacturers in China, including Sinovac, have received orders
from the government for more than 34 million doses. Among the 12 million
inoculated so far, 1,235 have complained of side effects, ranging from sore
arms, rashes, and headaches, to anaphylactic shock and sudden drops in blood
pressure.
While the Chinese government has been criticized for its draconian public health
response to swine flu — using quarantines, cancelling school and detaining
entire planeloads of people when a single passenger appears to have flulike
symptoms — the country's officials say the strict measures helped stem the
spread of flu. So far, China reports about 36 deaths and 62,800 H1N1 cases —
compared with U.S. government estimates of 4,000 American deaths and 22 million
infections. China plans to immunize 65 million citizens, or 5% of the country's
population, by the end of the year. As in the U.S., health officials are
targeting high priority groups first, including the military, police,
health-care workers, teachers, students and those with chronic diseases.